ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Committee IK IL-2/LAK For Modified Group C

May 1, 1987

Wyden, Schroeder Bill Would Require NIH To Test RU 486

October 23, 1992

Niederhuber says his job is easy, but times are hard: NCI may need to cut up to $150 million.

December 9, 2005

An Unusual Week Of Deals In Oncology: Alliances, Sales, and Dramatic Moves

November 13, 1998

Komen Foundation Announces Second Grant Cycle For 1995

April 28, 1995

In Brief: Three, Perhaps Four May Be Recommended To Carter; Hugh Creech To Retire July 1

April 1, 1977